Chang’s subsequent study in 2017 further highlighted that dipeptidyl peptidase-4 inhibitors (DPP4is) reduced AF risk by 35% (HR: 0.65; p < 0.0001) in a nationwide Taiwanese cohort of 90,880 patients [16]. The gene discussed is DPP4; the disease is atrial fibrillation.